Parkinson’s disease is a progressive neurological disorder associated with the loss of dopamine-producing neurons in the substantia nigra. Drugs used in its management aim to improve motor symptoms such as tremor, rigidity, and bradykinesia.
In this article, practise 30 important multiple-choice questions (MCQs) on antiparkinsonian drugs, including levodopa, carbidopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergic drugs.
These questions are useful for GPAT, RRB Pharmacist, DSSSB Pharmacist, B.Pharm, and D.Pharm exam preparation.
Section 1: Basic Concepts and Drug Classification
1. Parkinson’s disease is primarily associated with the degeneration of dopaminergic neurons in which part of the brain?
A. Cerebellum
B. Substantia nigra pars compacta
C. Hippocampus
D. Medulla oblongata
Correct Answer: B. Substantia nigra pars compacta
Explanation: Parkinson’s disease involves the degeneration of dopamine-producing neurons in the substantia nigra pars compacta. The resulting dopamine deficiency in the striatum contributes to characteristic motor symptoms.
2. Which drug is a precursor of dopamine and is widely used to improve the motor symptoms of Parkinson’s disease?
A. Levodopa
B. Carbidopa
C. Selegiline
D. Entacapone
Correct Answer: A. Levodopa
Explanation: Levodopa crosses the blood–brain barrier and is converted into dopamine in the brain. Dopamine itself does not cross the blood–brain barrier effectively.
3. Carbidopa is usually combined with levodopa because it:
A. Directly stimulates dopamine receptors
B. Inhibits peripheral conversion of levodopa into dopamine
C. Blocks dopamine receptors in the brain
D. Increases dopamine breakdown
Correct Answer: B. Inhibits peripheral conversion of levodopa into dopamine
Explanation: Carbidopa inhibits peripheral aromatic L-amino acid decarboxylase. This increases the amount of levodopa available to enter the brain and reduces some peripheral adverse effects, such as nausea. Carbidopa does not significantly cross the blood–brain barrier.
4. Which of the following is a dopamine receptor agonist used in Parkinson’s disease?
A. Pramipexole
B. Entacapone
C. Carbidopa
D. Amantadine
Correct Answer: A. Pramipexole
Explanation: Pramipexole directly stimulates dopamine receptors. Dopamine agonists can be used alone in selected patients or alongside levodopa, depending on symptoms and individual circumstances.
5. Which drug inhibits monoamine oxidase-B (MAO-B), an enzyme involved in dopamine breakdown?
A. Selegiline
B. Trihexyphenidyl
C. Benztropine
D. Carbidopa
Correct Answer: A. Selegiline
Explanation: Selegiline inhibits MAO-B and reduces dopamine breakdown in the brain. Rasagiline and safinamide are other MAO-B inhibitors used in Parkinson’s disease.
6. Which drug inhibits catechol-O-methyltransferase (COMT) and is used as an adjunct to levodopa?
A. Entacapone
B. Bromocriptine
C. Amantadine
D. Trihexyphenidyl
Correct Answer: A. Entacapone
Explanation: Entacapone inhibits peripheral COMT, reducing the metabolism of levodopa and extending its availability. It is used with levodopa to help manage wearing-off symptoms.
7. Which of the following is an anticholinergic drug that may be used for selected patients with Parkinson’s disease?
A. Trihexyphenidyl
B. Levodopa
C. Rasagiline
D. Entacapone
Correct Answer: A. Trihexyphenidyl
Explanation: Trihexyphenidyl reduces central muscarinic cholinergic activity. It may help selected patients, particularly those with troublesome tremor, but its cognitive and other anticholinergic adverse effects limit its use.
8. Which drug may be used to reduce levodopa-induced dyskinesia?
A. Amantadine
B. Carbidopa alone
C. Benztropine
D. Bromocriptine
Correct Answer: A. Amantadine
Explanation: Amantadine has multiple actions, including NMDA receptor antagonism. It can help reduce levodopa-induced dyskinesia in some patients.
9. Which statement about levodopa is correct?
A. It is a direct dopamine receptor antagonist.
B. It is converted into dopamine in the brain.
C. It cannot cross the blood–brain barrier.
D. It inhibits COMT directly as its principal action.
Correct Answer: B. It is converted into dopamine in the brain.
Explanation: Levodopa is a dopamine precursor that can cross the blood–brain barrier. Once inside the brain, it is converted into dopamine, helping compensate for reduced dopaminergic activity.
10. Which neurotransmitter system becomes relatively overactive compared with dopamine signalling in the striatum in Parkinson’s disease?
A. Cholinergic system
B. Insulin signalling system
C. Histamine system exclusively
D. Peripheral adrenergic system exclusively
Correct Answer: A. Cholinergic system
Explanation: Dopamine loss disrupts the balance between dopaminergic and cholinergic activity in the striatum. Central anticholinergic drugs can improve some symptoms in selected patients, although they are not suitable for everyone.
Section 2: Mechanism of Action
11. What is the primary mechanism of action of pramipexole?
A. Inhibition of peripheral dopamine synthesis
B. Direct stimulation of dopamine receptors
C. Irreversible blockade of dopamine receptors
D. Inhibition of acetylcholine synthesis
Correct Answer: B. Direct stimulation of dopamine receptors
Explanation: Pramipexole acts as a dopamine receptor agonist, particularly at D2-like receptors. It stimulates dopamine receptors without needing conversion into dopamine.
12. How does selegiline help manage Parkinson’s disease?
A. By increasing dopamine breakdown
B. By inhibiting MAO-B-mediated dopamine breakdown
C. By blocking all dopamine receptors
D. By inhibiting levodopa absorption in the intestine
Correct Answer: B. By inhibiting MAO-B-mediated dopamine breakdown
Explanation: MAO-B participates in dopamine metabolism in the brain. Inhibiting this enzyme can increase dopaminergic activity and help improve symptoms.
13. Entacapone is most commonly used with levodopa to:
A. Shorten levodopa’s duration of action
B. Extend levodopa’s effect and reduce wearing-off
C. Block dopamine receptors
D. Prevent all levodopa-associated dyskinesia
Correct Answer: B. Extend levodopa’s effect and reduce wearing-off
Explanation: Entacapone inhibits peripheral COMT and helps maintain levodopa availability. It can reduce end-of-dose wearing-off, although it may also worsen dyskinesia in some patients.
14. What is the principal action of trihexyphenidyl?
A. Muscarinic receptor antagonism in the central nervous system
B. Direct conversion into dopamine
C. Selective inhibition of COMT
D. Stimulation of peripheral insulin release
Correct Answer: A. Muscarinic receptor antagonism in the central nervous system
Explanation: Trihexyphenidyl blocks central muscarinic acetylcholine receptors. It may help reduce tremor in selected patients but can cause dry mouth, blurred vision, constipation, and confusion.
15. Which statement best describes the action of amantadine in Parkinson’s disease?
A. It acts only by inhibiting peripheral COMT.
B. It has multiple actions, including NMDA receptor antagonism.
C. It irreversibly blocks dopamine receptors.
D. It prevents levodopa from entering the brain.
Correct Answer: B. It has multiple actions, including NMDA receptor antagonism.
Explanation: Amantadine has complex pharmacological actions, including effects on glutamatergic signalling. It may improve some Parkinson’s symptoms and reduce levodopa-induced dyskinesia.
Section 3: Adverse Effects and Drug Interactions
16. Which of the following is a recognised adverse effect of long-term levodopa therapy?
A. Dyskinesia
B. Permanent protection against disease progression
C. Complete prevention of hallucinations
D. Guaranteed elimination of tremor
Correct Answer: A. Dyskinesia
Explanation: Long-term levodopa therapy may be associated with involuntary movements called dyskinesias and motor fluctuations. These effects vary among patients and may require treatment adjustments.
17. Which adverse effect is particularly associated with dopamine agonists such as pramipexole?
A. Impulse-control disorders
B. Severe tooth decay in every patient
C. Permanent loss of hearing in every patient
D. Complete suppression of appetite in every patient
Correct Answer: A. Impulse-control disorders
Explanation: Dopamine agonists can cause impulse-control disorders, including compulsive gambling, shopping, eating, or sexual behaviour. They may also cause sleepiness, hallucinations, and postural hypotension.
18. Which adverse effect is commonly associated with anticholinergic drugs such as trihexyphenidyl?
A. Dry mouth and constipation
B. Increased salivation in every patient
C. Severe hypoglycaemia as the principal effect
D. Increased intestinal motility
Correct Answer: A. Dry mouth and constipation
Explanation: Anticholinergic drugs can cause dry mouth, constipation, blurred vision, urinary retention, and cognitive impairment. Confusion and memory problems are particularly concerning in older adults.
19. Which serious adverse effect is associated with tolcapone, a COMT inhibitor?
A. Potential severe liver injury
B. Complete prevention of dopamine metabolism
C. Universal permanent blindness
D. Severe hypoglycaemia in all patients
Correct Answer: A. Potential severe liver injury
Explanation: Tolcapone has been associated with serious hepatotoxicity. Its use requires strict attention to prescribing restrictions and liver monitoring according to current clinical guidance.
20. Which of the following can occur with levodopa therapy?
A. Orthostatic hypotension
B. Guaranteed hypertension in every patient
C. Complete prevention of nausea
D. Permanent elimination of all motor symptoms
Correct Answer: A. Orthostatic hypotension
Explanation: Levodopa may cause orthostatic hypotension, nausea, dizziness, and other adverse effects. Combining it with carbidopa reduces peripheral dopamine formation and can lessen some peripheral adverse effects.
21. Why should levodopa not be stopped abruptly without medical supervision?
A. Abrupt withdrawal can cause a serious worsening of symptoms and a potentially dangerous syndrome.
B. It always causes immediate kidney failure.
C. It permanently prevents dopamine formation.
D. It causes antibiotic resistance.
Correct Answer: A. Abrupt withdrawal can cause a serious worsening of symptoms and a potentially dangerous syndrome.
Explanation: Abrupt reduction or withdrawal of antiparkinsonian treatment can cause severe rigidity, fever, altered mental status, and autonomic instability. Medication changes should be guided by a qualified healthcare professional.
22. Which dietary factor may interfere with levodopa absorption or transport in some patients?
A. Dietary protein
B. Drinking plain water
C. Dietary fibre in every circumstance
D. Vitamin C in every circumstance
Correct Answer: A. Dietary protein
Explanation: Large amounts of dietary amino acids can compete with levodopa for intestinal absorption and transport across the blood–brain barrier. Patients experiencing fluctuations may benefit from discussing meal timing and protein distribution with their clinician or dietitian.
23. Which statement about iron supplements and levodopa is correct?
A. Iron can reduce levodopa absorption when taken together.
B. Iron always increases levodopa effectiveness.
C. Iron converts levodopa directly into dopamine in the stomach.
D. Iron prevents all adverse effects of levodopa.
Correct Answer: A. Iron can reduce levodopa absorption when taken together.
Explanation: Iron supplements can reduce levodopa absorption in some circumstances. Patients should ask their pharmacist or prescriber how to separate doses when necessary.
24. Which adverse effect should be considered in a patient taking a dopamine agonist who reports suddenly falling asleep during daily activities?
A. Excessive daytime sleepiness or sudden sleep episodes
B. Improved alertness in all circumstances
C. Complete loss of pain sensation
D. Increased bone growth
Correct Answer: A. Excessive daytime sleepiness or sudden sleep episodes
Explanation: Dopamine agonists can cause excessive sleepiness and sudden sleep episodes. Patients should promptly discuss these symptoms with their clinician and avoid driving or other hazardous activities until appropriately assessed.
Section 4: Clinical and Exam-Based Questions
25. A patient experiences a return of Parkinson’s symptoms before the next scheduled levodopa dose. This is called:
A. Wearing-off phenomenon
B. Antibiotic resistance
C. First-pass elimination
D. Receptor upregulation only
Correct Answer: A. Wearing-off phenomenon
Explanation: Wearing-off occurs when the benefit of a levodopa dose diminishes before the next dose. Treatment adjustments or adjunctive drugs may be considered by the treating clinician.
26. A patient develops involuntary twisting movements after levodopa doses. Which term best describes this adverse effect?
A. Dyskinesia
B. Bradykinesia
C. Akinesia
D. Aphasia
Correct Answer: A. Dyskinesia
Explanation: Dyskinesia refers to involuntary movements that can occur with dopaminergic treatment, particularly levodopa. It is distinct from bradykinesia, which means slowness of movement.
27. A patient develops parkinsonian symptoms after taking a dopamine-blocking antipsychotic. Which statement is most appropriate?
A. The medication may be causing drug-induced parkinsonism.
B. The patient must have a dopamine-producing tumour.
C. Levodopa must always be started immediately without assessment.
D. The symptoms cannot be related to medication.
Correct Answer: A. The medication may be causing drug-induced parkinsonism.
Explanation: Dopamine receptor-blocking medicines can cause parkinsonian symptoms. The causative medicine should be reviewed by the prescriber; treatment depends on the cause and the patient’s clinical condition.
28. Which drug class directly stimulates dopamine receptors rather than serving as a dopamine precursor?
A. Dopamine agonists
B. COMT inhibitors
C. MAO-B inhibitors
D. Peripheral dopa-decarboxylase inhibitors
Correct Answer: A. Dopamine agonists
Explanation: Dopamine agonists, such as pramipexole and ropinirole, directly stimulate dopamine receptors. Levodopa works differently because it is converted into dopamine in the brain.
29. Which statement about the treatment of Parkinson’s disease is correct?
A. Current drug treatments can improve symptoms but do not reliably stop disease progression.
B. Levodopa permanently cures Parkinson’s disease.
C. Anticholinergics are suitable for every patient regardless of age.
D. Every patient must receive the same drug combination.
Correct Answer: A. Current drug treatments can improve symptoms but do not reliably stop disease progression.
Explanation: Antiparkinsonian drugs improve symptoms and quality of life, but they are not established cures. Treatment is individualised according to symptoms, age, daily functioning, adverse effects, and other clinical factors.
30. Which of the following is the most appropriate general principle for managing Parkinson’s disease medication?
A. Stop treatment whenever symptoms improve.
B. Adjust treatment according to individual response and adverse effects under medical supervision.
C. Double every dose when tremor increases.
D. Combine all antiparkinsonian drugs in every patient.
Correct Answer: B. Adjust treatment according to individual response and adverse effects under medical supervision.
Explanation: Parkinson’s disease treatment requires individualised assessment. Medication changes should account for motor symptoms, motor fluctuations, adverse effects, other medicines, and the patient’s daily needs.
📑Quick Revision: Important Parkinson’s Disease Drugs
- Levodopa: Dopamine precursor; improves motor symptoms.
- Carbidopa: Inhibits peripheral conversion of levodopa into dopamine.
- Pramipexole: Dopamine receptor agonist.
- Ropinirole: Dopamine receptor agonist.
- Selegiline: MAO-B inhibitor.
- Rasagiline: MAO-B inhibitor.
- Entacapone: Peripheral COMT inhibitor; helps reduce wearing-off when added to levodopa.
- Tolcapone: COMT inhibitor associated with serious liver injury risk.
- Amantadine: May reduce levodopa-induced dyskinesia.
- Trihexyphenidyl: Anticholinergic; may help selected patients with tremor.
📋Frequently Asked Questions
1. Which drug is considered the most effective for improving the motor symptoms of Parkinson’s disease?
Levodopa is generally the most effective medicine for improving the motor symptoms of Parkinson’s disease, although treatment selection depends on the individual patient.
2. Why is carbidopa combined with levodopa?
Carbidopa reduces the peripheral conversion of levodopa into dopamine, allowing more levodopa to reach the brain and reducing certain peripheral adverse effects.
3. Which drugs are MAO-B inhibitors?
Selegiline, rasagiline, and safinamide are MAO-B inhibitors used in the management of Parkinson’s disease.
4. Which drug can help reduce levodopa-induced dyskinesia?
Amantadine can reduce levodopa-induced dyskinesia in some patients.
🎯 Conclusion
Practise these 30 Parkinson’s disease drugs MCQs to revise important drug classes, mechanisms of action, adverse effects, and clinical concepts. For better preparation, review the detailed notes and then attempt the questions again without looking at the answers.
Educational disclaimer: This article is intended for pharmacy education and exam preparation. It is not a substitute for professional medical advice or individualised treatment.
1 thought on “Top 30 MCQs on Parkinson’s Disease Drugs with Answers & Explanation”